ReviewEpidemics2012
Optimal but unequitable prophylactic distribution of vaccine.
Review in Epidemics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Optimizing vaccine allocation: a review of epidemiological models with behavioral adaptation.Clinical and experimental vaccine research · 2026Review
- A stochastic framework to assess the optimal allocation of limited vaccine doses in foot-and-mouth disease outbreaks using game theory.Frontiers in veterinary science · 2026Article
- Effectiveness and equity of vaccination strategies against Rift Valley fever in a heterogeneous landscape.PLoS neglected tropical diseases · 2025Article
- Comparative performance of between-population vaccine allocation strategies with applications for emerging pandemics.Vaccine · 2023Article
- Optimal vaccination at high reproductive numbers: sharp transitions and counterintuitive allocations.Proceedings. Biological sciences · 2022Article
- Where to locate COVID-19 mass vaccination facilities?Naval research logistics · 2022Article
- Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2.Scientific reports · 2022Article
- Evaluating strategies for spatial allocation of vaccines based on risk and centrality.Journal of the Royal Society, Interface · 2022Article
- Blockchain Powered Vaccine Efficacy for Pharma Sector.Computational and mathematical methods in medicine · 2022Review
- Optimal strategies to protect a sub-population at risk due to an established epidemic.Journal of the Royal Society, Interface · 2022Article
- Blockchain Enabled Transparent and Anti-Counterfeiting Supply of COVID-19 Vaccine Vials.Vaccines · 2021Article
- Vaccine nationalism and the dynamics and control of SARS-CoV-2.Science (New York, N.Y.) · 2021Article
- Towards efficacy and sustainability of global, regional and national COVID-19 vaccination programs.Journal of global health · 2021Review
- The future of a partially effective HIV vaccine: assessing limitations at the population level.International journal of public health · 2019Article
- Incentivizing hospital infection control.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- A theoretical single-parameter model for urbanisation to study infectious disease spread and interventions.PLoS computational biology · 2019Article
- Global stability analysis for a generalized delayed SIR model with vaccination and treatment.Advances in difference equations · 2019Article
- Dose-Optimal Vaccine Allocation over Multiple Populations.Production and operations management · 2018Article
- Article
- Reactive vaccination in the presence of disease hotspots.Proceedings. Biological sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The final epidemic size (R(∞)) remains one of the fundamental outcomes of an epidemic, and measures the total number of individuals infected during a "free-fall" epidemic when no additional control action is taken. As such, it provides an idealised measure for optimising control policies before an epidemic arises. Although the generality of formulae for calculating the final epidemic size have been discussed previously, we offer an alternative probabilistic argument and then use this formula to consider the optimal deployment of vaccine in spatially segregated populations that minimises the total number of cases. We show that for a limited stockpile of vaccine, the optimal policy is often to immunise one population to the exclusion of others. However, as greater realism is included, this extreme and arguably unethical policy, is replaced by an optimal strategy where vaccine supply is more evenly spatially distributed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.